CARLSBAD, Calif. & NEW YORK & SAN FRANCISCO -- (BUSINESS WIRE) -- Biotech Showcase™ 2013 investor and partnering conference, to be held January 7–9, 2013 in San Francisco, CA at Parc 55 Wyndham San Francisco - Union Square, is an innovation showcase for life science investors.
This year’s program kicks off on Monday, January 7 with parallel workshops. The first, entitled “The Watch List of 2013,” is a workshop in which top biotech analysts discuss the driving macro trends and specific opportunities for 2013 and how investors can capitalize on them. The second workshop is on “How asset-centric biotech structures can open new avenues for achieving liquidity.” The lunch plenary, intriguingly called “Deciding to go commercial in the go-it-alone era: Can we resolve the risk vs. the reward?”, will be moderated by Jeff Stewart of Campbell Alliance, with panelists Ron Cohen of Acorda Therapeutics; Shaun Grady of AstraZeneca; Dennis J. Purcell of Aisling Capital LLC; and Mary C. Tanner of Peter J. Solomon Company.
“The question really is, what will the next generation of companies look like?” said Dennis Purcell. “It can be a tough, long road to commercialization for emerging companies, and they have to make important decisions in choosing whether to pursue a deal or go at it alone. I think there are a lot of questions about how to build critical milestones into the business plan to enable companies to make the right decision. It should be an interesting group discussion.”
Tuesday will feature more workshops ranging from oncology reimbursement to eHealth: Medicine's next frontier, with a special track presented by the Alliance for Regenerative Medicine.
Tuesday’s lunch plenary, “Funding biotech: Do we need a superfund?” will feature inspired discussion led by Brady Huggett of Nature Publishing Group on a March 2012 op-ed piece by Mark Kessel of Symphony Capital published in The Scientist calling for the establishment of a biotech superfund to be funded by pharma. Panelists include Frances K. Heller of Bristol-Myers Squibb; Martin Mackay of AstraZeneca; Harri V. Taranto of Symphony Capital; Mary Woolley of Research!America; and Daphne Zohar of PureTech Ventures.
“The creation of biotech seed investment funds by pharmaceutical companies is gaining in popularity to offset cuts in R&D funding,” said Martin Mackay. “These funds are innovative for their ability to allow pharma to focus investments on early stage companies which reinvigorate our product pipeline for new drug development. The prospect of these investments is win-win, and I think it will be a provocative panel discussion.”
Wednesday will wrap up with parallel workshops on FDA changes, obesity, open innovation and a panel on spinal cord injury investment opportunities and challenges moderated by Bill Barrable of the Rick Hansen Institute.
Company presentations will be given during all three conference days.
Biotech Showcase is co-produced annually by EBD Group, Inc. and Demy-Colton Life Science Advisors. Both organizations have a long history of providing high quality business support programs and services to the biotechnology industry.
“Biotech Showcase is geared toward emerging private and public life science companies and biotech,” said Carola Schropp, President of EBD Group. “The focus of the program is consistent with the objective of attending companies, to uncover commercialization and investment opportunities and challenges, and to participate in presentations from companies.”
“The continued success of the highly anticipated Biotech Showcase is reflective of the high demand for emerging biotech companies to connect with private and public investors,” said Sara Jane Demy, President of Demy-Colton Life Science Advisors. “With the largest gathering of life science investors in San Francisco during January, there really is no comparison to the high level of access available to Biotech Showcase delegates and presenting companies.”
Participants include private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives as well as other industry professionals. The 2013 edition will feature nearly 230+ corporate presentations as well as a robust program that will address the current environment for investment and growth, best practices, important therapeutic areas and business development.
Biotech Showcase is powered by partneringONE®, the industry’s most advanced partnering system, that enables delegates to efficiently identify and arrange meetings with potential investors and partners. Partnering opened December 5. Start requesting meetings by logging onto your account at http://www.ebdgroup.com/bts/partnering/index.php.
About Biotech Showcase™ 2013:
Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
The 2012 event showed a substantial increase in the number of presenting companies, as well as significant growth in the number of attendees and one-to-one meetings. Now in its fifth year, Biotech Showcase 2013 is expected to feature presentations by close to 250 public and private companies and attract more than 1,500 attendees. The event will host a full program of topical plenary sessions and workshops.
Follow Biotech Showcase 2013 on Twitter: twitter.com/ebdgroup (hashtag: #BTS13)
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
EBD Group’s sophisticated web-based partnering service, partneringONE®, is also used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences all year long. Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
About Demy-Colton Life Science Advisors
Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life science industry. Demy-Colton has developed a number of high-value added conferences to address the business and development needs of the biotechnology industry; it provides partnering services and it has helped launch a unique investor website and newsletter.
Demy-Colton's conferences include:
Demy-Colton's online partnering systems, Collaborate™ and CollaborateTeam™ support Demy-Colton's events and facilitates investor and venture meetings for the pharma industry and partnering for other organizations.
Demy-Colton Life Science Advisors has also been involved in the launch and development of The Life Sciences Report, a unique investor newsletter where third party experts share their opinions on investment opportunities. To subscribe to this free newsletter, click here. To become a sponsor, please contact Sara Jane Demy at email@example.com.
For more information please visit www.demy-colton.com